SELLAS Life Sciences Group, Inc. financial data

Symbol
SLS on Nasdaq
Industry
Pharmaceutical Preparations
Location
7 Times Square, Suite 2503, New York, NY
State of incorporation
Delaware
Fiscal year end
December 31
Former names
GALENA BIOPHARMA, INC. (to 12/15/2017), Galena Biopharma, Inc. (to 12/15/2017), RXI PHARMACEUTICALS CORP (to 9/21/2011)
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 81.2 % -43.5%
Debt-to-equity 6.68K % +3906%
Return On Assets -256 % -67.7%
Operating Margin -4.2K % -1160%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 64.3M shares +127%
Common Stock, Shares, Outstanding 57.8M shares +104%
Entity Public Float 44.4M USD -3.03%
Common Stock, Value, Issued 5K USD +66.7%
Weighted Average Number of Shares Outstanding, Basic 57.6M shares +103%
Weighted Average Number of Shares Outstanding, Diluted 57.6M shares +103%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Costs and Expenses 34.8M USD -5.74%
Operating Income (Loss) -34.8M USD +5.74%
Nonoperating Income (Expense) 365K USD -28.1%
Net Income (Loss) Attributable to Parent -34.4M USD +4.55%
Earnings Per Share, Basic -0.9 USD/shares +37.9%
Earnings Per Share, Diluted -0.9 USD/shares +37.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9.15M USD -33.8%
Accounts Receivable, after Allowance for Credit Loss, Current 1M USD
Assets, Current 12.3M USD -21%
Operating Lease, Right-of-Use Asset 633K USD -8.26%
Goodwill 1.91M USD 0%
Assets 15.1M USD -18.6%
Accounts Payable, Current 6.33M USD +69.6%
Employee-related Liabilities, Current 1.74M USD +56.3%
Accrued Liabilities, Current 5.18M USD -16.9%
Liabilities, Current 12M USD -10.3%
Operating Lease, Liability, Noncurrent 161K USD -46.7%
Liabilities 12.2M USD -11.1%
Retained Earnings (Accumulated Deficit) -234M USD -17.2%
Stockholders' Equity Attributable to Parent 2.91M USD -39.9%
Liabilities and Equity 15.1M USD -18.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.8M USD +11.3%
Net Cash Provided by (Used in) Financing Activities 26.6M USD +41%
Common Stock, Shares Authorized 350M shares 0%
Common Stock, Shares, Issued 57.8M shares +104%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 15.9M USD +134%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9.25M USD -33.5%
Deferred Tax Assets, Valuation Allowance 18.8M USD +15.2%
Deferred Tax Assets, Gross 19M USD +15%
Operating Lease, Liability 692K USD -7.61%
Lessee, Operating Lease, Liability, to be Paid 745K USD -6.17%
Operating Lease, Liability, Current 531K USD +18.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 477K USD -10.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 477K USD -10.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure -7.17%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 53K USD +17.8%
Deferred Tax Assets, Operating Loss Carryforwards 12.2M USD +16.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Operating Lease, Payments 500K USD 0%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 184K USD 0%
Share-based Payment Arrangement, Expense 1.85M USD -5.37%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%